PRINCIPLES OF COLLABORATION. The parties agree to adopt the following principles when carrying out the Project (Principles):
(a) collaborate and co-operate. Establish and adhere to the governance structure set out in this MoU to ensure that activities are delivered and actions taken as required;
(b) be accountable. Take on, manage and account to each other for performance of the respective roles and responsibilities set out in this MoU;
PRINCIPLES OF COLLABORATION. The parties agree to adopt the following principles when carrying out the Project (Principles):
(a) collaborate and co-operate. Establish and adhere to the existing governance structures, applicable to both councils under its normal decision making processes, and in terms of project delivery, as set out in the Annexe B, to ensure that activities are delivered and actions taken as required;
(b) be accountable. Take on, manage and account to each other for performance of the respective roles and responsibilities, as agreed through the Project Board;
PRINCIPLES OF COLLABORATION. The parties agree to adopt the following principles when carrying out the Project (Principles):
(a) collaborate and co-operate. Establish and adhere to the governance structure set out in this MoU to ensure that activities are delivered and actions taken as required;
(b) be accountable. Take on, manage and account to each other for performance of the respective roles and responsibilities set out in this MoU;
(c) be open. Communicate openly and share information about major concerns, issues or opportunities relating to the Project;
(d) learn, develop and seek to achieve full potential. Share information, experience, materials and skills to learn from each other and develop effective working practices, work collaboratively to identify solutions, eliminate duplication of effort, mitigate risk and reduce cost;
(e) adopt a positive outlook. Behave in a positive, proactive manner;
(f) adhere to statutory requirements and best practice. Comply with applicable laws and standards including EU procurement rules, data protection and freedom of information legislation.
(g) act in a timely manner. Recognise the time-critical nature of the Project and respond accordingly to requests for support;
(h) manage stakeholders effectively;
(i) deploy appropriate resources. Ensure sufficient and appropriately qualified resources are available and authorised to fulfil the responsibilities set out in this MoU. In particular the parties agree to make the contributions detailed in Annex C to this MoU;
(j) act in good faith to support achievement of the Key Objectives and compliance with these Principles; and
(k) adopt a joint approach to communication. Plan and manage communications jointly, wherever practically possible to share and agree communications before they are issued.
PRINCIPLES OF COLLABORATION. The parties agree to adopt the following principles of collaboration when working together (Principles):
3.1 collaborate and co-operate to ensure that any agreed activities are delivered and actions taken as required;
3.2 be accountable. Take on, manage and account to each other for performance of the respective roles and responsibilities that relate to any shared activities that have been agreed by the signatories to this MoU;
PRINCIPLES OF COLLABORATION. 1 To establish and adhere to the governance structure set out in this Agreement to ensure that activities are delivered and actions taken as required.
PRINCIPLES OF COLLABORATION. The Councils agree to act in good faith and to adopt the behaviours set out in Part 2 of Schedule 1 when working jointly.
PRINCIPLES OF COLLABORATION. (1) It is necessary that the COLLABORATION PARTNER complies with each of the fol- lowing requirements, otherwise GMC
a. has at its sole discretion the right to reject MOUSELINE or b. may not to carry out one or more particular tests. GMC may in exceptional cases agree to some changes of the requirements (for in- stance the number of mice), if it is informed about and has agreed to it before re- ceiving the mice. If GMC accepts a change in its procedure, the COLLABORATION PARTNER accepts that changes may have an impact on the results. However, GMC shall not be obliged to accept the COLLABORATION PARTNER’s request, but may decide to reject it for internal reasons.
(2) If GMC rejects the phenotypic analysis because the COLLABORATION PARTNER did not fulfill one or more of the requirements of section 1 (3), the COLLABORATION PARTNER is obliged to reimburse GMC for all incurred expenses in connection with the intended collaboration.
(3) The COLLABORATION PARTNER shall deliver the following to GMC:
a. 60 mice [15 males and 15 females (mutants) and 15 males and 15 females (wildtype); the wildtype animals should be littermates of the mutant animals; the animals have to be sent when they are 7 weeks old and genotyped; the maximum age difference between youngest and oldest is 7 days (a high num- ber of mice is necessary to ensure an optimal screen performance)]: - hereinafter referred to as the “MOUSELINE” - The MOUSELINE must have a confirmed genetic modification or defined treatment. The mice have to bear the ear marking used in the GMC. The GMC can reject the import of mice that bear a different marking for identification.
b. The duly completed request form (see section “requests” on xxx.xxxxxxxxxxx.xx) concerning distinctive features of the MOUSELINE has to be filled in with correct information. The request procedure follows the steps outlined on the GMC website (xxx.xxxxxxxxxxx.xx).
c. An overview of the MOUSELINE and its specific mutation, the documentation of the confirmation of the mutation and about the already known and con- firmed phenotypes (according to the example provided in section “requests” on xxx.xxxxxxxxxxx.xx); the overview should include a publication list.
d. Copies of the three most important publications about the MOUSELINE or gene (if such publications exist);
e. A health report according to the FELASA recommendations (see section “re- quests” on xxx.xxxxxxxxxxx.xx); this information is vital for the decision if a MOUSELINE can be imported i...
PRINCIPLES OF COLLABORATION. 3.1. Working together on strategic priorities irrespective of local authority boundaries.
3.2. Creating collective scale, resilience, and impact for the benefit of our residents and businesses.
3.3. Tackling problems and issues that we cannot solve individually.
3.4. Collaborating to gain something, without losing something (including local identities).
3.5. Governance arrangements proportionate to our shared ambition.
3.6. Opportunities to discharge certain functions jointly, and pooling of resources, should be considered where this can have collective and measurable impact.
PRINCIPLES OF COLLABORATION. 3.1 This collaborative procedure is applicable to: ■ pharmaceutical products that have been assessed and inspected by WHO/PQT in line with the procedures and standards available at xxx.xxx.xxx/xxxxxxx (“Information for applicants”) and have been found to be acceptable in principle for procurement by UN agencies as listed in the List of WHO prequalified medicines, available at www. xxx.xxx/xxxxxxx. The Procedure is not applicable to pharmaceutical products that have been listed as prequalified on the basis of approval by stringent regulatory authorities (SRAs).2 For such products the principal part of the assessment has been performed by SRAs and WHO/PQT is not in possession of assessment and inspection reports that can be shared; ■ vaccines that have been assessed and inspected by WHO/PQT in line with the procedures and standards available at xxxx://xxx. xxx.xxx/xxxxxxxxxxxx_xxxxxxxxx/xxxxxxx_xxxxxxx/xx_xxxxxx/xx/ and have been found to be acceptable in principle for procurement by UN agencies as listed in the List of WHO prequalified vaccines, available at xxxx://xxx.xxx.xxx/immunization_standards/vaccine_ quality/PQ_vaccine_list_en/en/. This Procedure is applicable to 2 Products listed as prequalified according to the procedure described in the Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty‑eighth report. Geneva: World Health Organization; 2014: Annex 5 (WHO Technical Report Series, No. 986). vaccines that successfully passed either the standard or streamlined prequalification process: xxxx://xxx.xxx.xxx/immunization_ standards/vaccine_quality/pq_revision2010/en/). Although the Procedure mostly serves to accelerate the assessment and registration of prequalified multisource (generic) pharmaceutical products it is applicable to vaccines and any pharmaceutical product for which the safety and efficacy has been documented to WHO/PQT by the submission of preclinical and clinical data. The Procedure has three major stakeholders: WHO/PQT, interested NRAs and those WHO PQ holders or applicants3 who agree that this Procedure is used for applications for national registration of their WHO-prequalified product submitted to an NRA.
3.2 WHO/PQT and participating authorities receive applications for the same pharmaceutical product or vaccine. Within the context of this Procedure, the same p...
PRINCIPLES OF COLLABORATION. The Parties agree that, to the extent which it is reasonably practicable, this Agreement shall operate on a collaborative basis and to this end each Party agrees to use all reasonable endeavours to adhere to the Principles of Collaboration.
